Davis Capital Management
ADMA icon

Davis Capital Management’s ADMA Biologics ADMA Stock Holding History

Davis Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$130 Hold
13
– – ﹤0.01% 972
2026
Q2 		$109 Buy
+13
New +$119 ﹤0.01% 1040

Other funds holding ADMA

Marathon Capital Management
Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Motley Fool Asset Management
Motley Fool Asset Management Alexandria, Virginia $2.64B AUM 26.58% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Davis Capital Management's ADMA Position: Q3 2026 in Review

Davis Capital Management held its ADMA Biologics (ADMA) position steady in Q3 2026 at 13 shares worth $130. The position accounts for ﹤0.01% of the portfolio, ranked #972.

Davis Capital Management first reported a position in ADMA in Q2 2026 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Davis Capital Management held 13 shares of ADMA Biologics worth $130 as of Q3 2026.
  • Davis Capital Management left its ADMA Biologics share count unchanged in Q3 2026.
  • ADMA Biologics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #972 holding.
  • Davis Capital Management first reported a position in ADMA Biologics in Q2 2026 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.